产品
编 号：F276287
分子式：C15H18N2O
分子量：242.32
分子式：C15H18N2O
分子量：242.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 218457-67-1
产品详情
生物活性：
Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity.
体内研究：
Limantrafin inhibits NOTCH dependent cellular processes in mice.Limantrafin blocks in vivo growth of PDX models of T-ALL.Limantrafin (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.Limantrafin exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.Animal Model:NSG mice, triple negative breast cancer mouse xenograft model
Dosage:25 mg/kg
Administration:Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks
Result:Inhibited growth of GSI/Mab resistant triple negative breast cancer.
体外研究：
Limantrafin acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.Limantrafin can block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.Limantrafin exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity.
体内研究：
Limantrafin inhibits NOTCH dependent cellular processes in mice.Limantrafin blocks in vivo growth of PDX models of T-ALL.Limantrafin (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.Limantrafin exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.Animal Model:NSG mice, triple negative breast cancer mouse xenograft model
Dosage:25 mg/kg
Administration:Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks
Result:Inhibited growth of GSI/Mab resistant triple negative breast cancer.
体外研究：
Limantrafin acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.Limantrafin can block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.Limantrafin exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备